Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
FRONTIERS IN NEUROLOGY(2022)
Abstract
IntroductionBlepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period. Case presentationWe herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine. ConclusionThe current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.
MoreTranslated text
Key words
blepharospasm,Parkinson's disease,peak-dose dyskinesia,amantadine,dyskinesia
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined